Andreas Busch has bought stock on 3 days since Nov 2020

Andreas Busch, Ph.D., is Chief Innovation Officer at Absci Corporation (ABSI), a role he has held since September 2022, employed via Absci GmbH. Age 61 as of March 31, 2025, he leads R&D, technical operations, and drives internal and partner programs at the generative AI drug creation company.( Under his tenure, Absci achieved 100% of corporate performance goals in 2023 and 2024, encompassing pipeline advancement, strategic partnerships, R&D milestones, AI platform development, and cash flow objectives.(

Busch brings extensive expertise from senior R&D leadership roles at major pharma companies, including Chief Scientific Officer and Chief Innovation Officer at Cyclerion Therapeutics (2019–2022), EVP and Head of R&D at Shire (2018–2019), Executive VP and Global Head of Drug Discovery at Bayer (2006–2017), and Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis. His leadership has resulted in over 10 commercial drugs from bench to FDA approval, with several more in late-stage clinical development.( He holds an Extraordinary Professorship in Pharmacology at Goethe University Frankfurt, where he earned his Ph.D., and serves on boards of institutions like the German Cancer Research Center and companies including Astellas Pharma.(

Written by Perplexity from public sources.